Annual Financial Report

RNS Number : 5058B

MGC Pharmaceuticals Limited

03 October 2022

 

MGC Pharmaceuticals Ltd.

Annual Financial Report for the year ended 30 June 2022

 and ASX Corporate Governance Statement

3 October 2022

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to provide the following documents in respect of the financial year ended 30 June 2022:

· Annual Financial Report (audited)

A copy of Company's Annual Financial Report for the year ended 30 June 2022 can be found at the following URL:

https://www.investi.com.au/api/announcements/mxc/952d8558-ef0.pdf

· ASX Appendix 4G "Key disclosures - Corporate Governance Council Principles and Recommendations" and MGC Pharma's Corporate Governance Statement

A copy of the Company's ASX Appendix 4G - Corporate Governance Disclosures can be found at the following URL:

https://www.investi.com.au/api/announcements/mxc/7f8e0698-2a3.pdf

A copy of Company's Corporate Governance Statement for the period ended 30 June 2022 can be found at the following URL:

https://mgcpharma.eu/asx-investor-centre/corporate-governance/

--Ends--

Authorised for release by the Chairman, for further information please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd David Lim Company Secretary [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [phone] [e-mail]	UK PR Advisors - Tavistock Charles Vivian / Tim Pearson [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. 

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities. 

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

ACSFSWSIDEESEDS